Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp, Lene Dreyer, Annette Hansen, Ib Tønder Hansen, Gina Kollerup, Louise Linde, Hanne M Lindegaard, Uta Engling Poulsen, Annette Schlemmer, Dorte Vendelbo Jensen, Signe Jensen, Gisela Hostenkamp, Mikkel Østergaard, All Departments, Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp, Lene DreyerAnnette Hansen, Ib Tønder Hansen, Gina Birgitte Kollerup, Louise Linde, Hanne Merete Lindegaard, Uta Engling Poulsen, Annette Schlemmer, Dorte Vendelbo Jensen, Signe Jensen, Gisela Hostenkamp, Mikkel Østergaard, All Departments of Rheumatology in Denmark

    415 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry'. Together they form a unique fingerprint.

    Keyphrases

    Pharmacology, Toxicology and Pharmaceutical Science

    Immunology and Microbiology